Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb completes $2.5bn acquisition of Inhibitex

Deal with US biopharmaceutical company boosts its presence in hepatitis C

Bristol-Myers Squibb (BMS) has acquired clinical stage biopharmaceutical company Inhibitex in a deal that boosts its presence in hepatitis C.

Inhibitex's lead compound is the oral nucleotide polymerase (NS5B) inhibitor INX-189, which is in phase II trials in combination with pegylated interferon and ribavirin for chronic hepatitis C.

The deal, which cost BMS approximately $2.5bn, is the latest phase in the pharma company's much-touted 'string of pearls' approach to drug development.

This relies on complementing internal R&D with a suite of alliances, partnerships and acquisitions in its core therapeutic areas and Georgia, US-based Inhibitex is the newest 'pearl' in the string of more than a dozen deals BMS has made since 2007

BMS has been signing a series of agreement in an attempt to combine its own hepatitis C drug candidates - led by NS5A replication complex inhibitor daclatasvir (BMS-790052) in phase III - with compounds in development at other companies.

The overall aim is to develop all-oral treatment regimens that could replace the current therapies based on injectable interferon alpha.

Analysts have predicted multibillion dollar sales for a number of oral hepatitis C therapies coming through pharma company pipelines, and the sector has been invigorated recently by approvals for new oral therapies.

These include Merck & Co's Victrelis (boceprevir) and J&J, Vertex Pharmaceuticals and Mitsubishi Tanabe's Incivek/Incivo (telaprevir).

In December 2011 BMS forged an alliance with Johnson & Johnson's Tibotec unit for the development of an all-oral combination therapy based on daclatasvir and Tibotec's NS3 protease inhibitor TMC435. Phase II trials of the regimen are due to start later this year.

14th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics